报价延迟最少15分钟:2025/08/16 09:28 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.83 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.66/-1.86
|
|
企业价值
223.67M
|
| 资产负债 |
|
每股账面净值
2.94
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/16 09:28 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing apipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. |
